AKT1 and hepatocellular carcinoma: Because Dasatinib has been shown to regulate additional targets, such as Stat3,24 NF‐κB,25 Ras/MAPK and AKT/mTOR26 pathways, we analyzed the expression of these targets in a panel of 4 mouse and human HCC cell lines (Figure S3).